Jiangsu Hengrui Pharmaceuticals Co., Ltd. published its monthly return on securities movements as of November 30, 2025. The announcement outlines changes to the company’s authorized and issued share capital across its H Shares and A Shares, as well as treasury share adjustments.
In terms of authorized share capital, the company’s H Shares remained constant at 258,197,600 shares at a par value of RMB1, while A Shares stayed at 6,379,002,274 shares. The total authorized share capital as of month-end stood at RMB 6,637,199,874.
The number of issued H Shares remained unchanged at 258,197,600. The issued A Shares closed the month at 6,375,263,324, and the balance of A Shares held as treasury shares was 3,738,950. During November, 12,531,160 A Shares were transferred out of treasury, primarily in connection with repurchases and transfers related to employee stock ownership schemes.
Key share repurchase transactions were executed on various dates through November 2025, involving shares held as treasury shares at prices ranging from RMB 59.52 to RMB 63.22. Meanwhile, 13,511,100 treasury shares were transferred in respect of awards granted under share schemes. The net impact was an increase in issued A Shares by 12,531,160 and a corresponding decrease in treasury shares by the same amount.
According to the announcement, the purchase and transfer of A Shares occurred under multiple A Share Employee Stock Ownership Schemes approved earlier in 2025. The company repurchased 979,940 A Shares in November and transferred a total of 13,511,100 A Shares to these schemes, maintaining a final treasury share balance of 3,738,950 A Shares as of the close of the month.
Comments